BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/14/2018 10:51:23 AM | Browse: 1066 | Download: 1590
 |
Received |
|
2018-08-27 01:02 |
|
Peer-Review Started |
|
2018-08-27 07:07 |
|
First Decision by Editorial Office Director |
|
2018-08-31 14:17 |
|
Return for Revision |
|
2018-09-11 00:31 |
|
Revised |
|
2018-09-17 10:52 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-11-01 03:04 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2018-11-02 22:09 |
|
Articles in Press |
|
2018-11-02 22:09 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-12-05 08:27 |
|
Publish the Manuscript Online |
|
2018-12-14 10:51 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu Sunakawa, Hironaga Satake and Wataru Ichikawa |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yu Sunakawa, MD, PhD, Associate Professor, Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki 216-8511, Kanagawa, Japan. y.suna0825@gmail.com |
| Key Words |
Tumor sidedness; FOLFOXIRI; Bevacizumab; Colorectal cancer; RAS mutation |
| Core Tip |
FOLFOXIRI plus bevacizumab regimen might be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC) regardless of RAS or BRAF status. However, subanalysis of a phase Ⅱ trial of the triplet plus bevacizumab in patients with RAS mutant mCRC demonstrated that more patients with left-sided tumors achieved good tumor shrinkage and long duration of treatment than did patients with right-sided tumors, leading to higher rate of conversion to surgery in mCRC patients with left-sided tumors. Our data suggest that FOLFOXIRI plus bevacizumab may be a promising treatment for left-sided mCRC associated with RAS mutant tumors. |
| Publish Date |
2018-12-14 10:51 |
| Citation |
Sunakawa Y, Satake H, Ichikawa W. Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors. World J Gastrointest Oncol 2018; 10(12): 528-531 |
| URL |
https://www.wjgnet.com/1948-5204/full/v10/i12/528.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v10.i12.528 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
